## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Confirmation No.: 5489

UMAÑA et al. Art Unit: 1633

Appl. No.: 10/633,699 Examiner: Burkhart, Michael D.

Filed: August 5, 2003 Atty. Docket: 1975.0010004/TJS/T-M

For: Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular

Cytotoxicity

Supplemental Amendment and Reply Under 37 C.F.R. §§ 1.111 and 1.114

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Supplemental to the Amendment and Reply Under 37 C.F.R. §§ 1.111 and 1.114 filed on May 14, 2008, and in further response to the Office Action mailed November 15, 2007, Applicants submit the following Supplemental Amendment and Reply. *The amendments herein are limited to the cancellation of certain claims*. Accordingly, this Supplemental Amendment and Reply meets the requirements of 37 C.F.R. § 1.111(a)(2)(i)(A) and should be entered.

Amendments to the Claims begin on page 3 of this paper.

Remarks begin on page 7 of this paper.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned

under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.